{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:43:46Z","timestamp":1686188626115},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s15010-011-0135-3","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T07:09:32Z","timestamp":1310022572000},"page":"433-437","source":"Crossref","is-referenced-by-count":1,"title":["Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience"],"prefix":"10.1007","volume":"39","author":[{"given":"D.","family":"Kozielewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Dybowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Halota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Dr\u00f3\u017cd\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"135_CR1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49:1335\u201374.","journal-title":"Hepatology"},{"key":"135_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cld.2009.05.012","volume":"13","author":"G Dusheiko","year":"2009","unstructured":"Dusheiko G. Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis. 2009;13:487\u2013501.","journal-title":"Clin Liver Dis"},{"key":"135_CR3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1600-0609.1991.tb01561.x","volume":"47","author":"A Osterborg","year":"1991","unstructured":"Osterborg A. Patients treated with natural (leukocyte-derived) interferon-alpha do not develop IFN antibodies (letter). Eur J Haematol. 1991;47:234.","journal-title":"Eur J Haematol"},{"key":"135_CR4","first-page":"63","volume":"1","author":"TW \u0141api\u0144ski","year":"2008","unstructured":"\u0141api\u0144ski TW, D\u0105browska MM, Flisiak R. Leukocytarny interferon naturalny alfa (IFN-\u03acN3) w leczeniu chorych przewlekle zaka\u017conych HCV. Zaka\u017cenia. 2008;1:63\u20137.","journal-title":"Zaka\u017cenia"},{"key":"135_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s15010-008-8164-2","volume":"37","author":"B Cacopardo","year":"2009","unstructured":"Cacopardo B, Nunnari G, Benanti F, et al. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons. Infection. 2009;37:210\u20135.","journal-title":"Infection"},{"key":"135_CR6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11739-009-0290-z","volume":"4","author":"LE Adinolfi","year":"2009","unstructured":"Adinolfi LE, Durante-Mangoni E, Salzillo M, et al. Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon. Intern Emerg Med. 2009;4:485\u201390.","journal-title":"Intern Emerg Med"},{"key":"135_CR7","first-page":"13","volume":"28","author":"N Napoli","year":"2005","unstructured":"Napoli N, Giannelli G, Parisi CV, et al. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiol. 2005;28:13\u201321.","journal-title":"New Microbiol"},{"key":"135_CR8","doi-asserted-by":"crossref","unstructured":"Aghemo A, Rumi M.G, Monico S, et al. Genotype dependent pattern of peginterferon alfa-2b\/ribavirin treatment failure in hepatitis C virus infected patients with cirrhosis: a single center study of 471 na\u00efve patients. J Hepatol. 2008;48:287.","DOI":"10.1016\/j.dld.2007.12.026"},{"key":"135_CR9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0168-8278(00)00097-0","volume":"43","author":"T Poynard","year":"2001","unstructured":"Poynard T, Ratzin V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;43:730\u20139.","journal-title":"J Hepatol"},{"key":"135_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0168-8278(04)00060-1","volume":"40","author":"S Zeuzem","year":"2004","unstructured":"Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993\u20139.","journal-title":"J Hepatol"},{"key":"135_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s15010-008-7319-5","volume":"36","author":"E Righi","year":"2008","unstructured":"Righi E, Beltrame A, Bassetti M, et al. Therapeutical aspects and outcome of HIV\/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection. 2008;36:358\u201361.","journal-title":"Infection"},{"key":"135_CR12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jac\/dkn421","volume":"62","author":"J Morello","year":"2008","unstructured":"Morello J, Rodriguez-Novoa S, Jim\u00e9nez-N\u00e1cher I, et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patient with chronic hepatitis C. J Antimicrob Chemother. 2008;62:1174\u201380.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"135_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2893.1998.00113.x","volume":"5","author":"B Cacopardo","year":"1998","unstructured":"Cacopardo B, Benanti F, Brancati G, et al. Leukocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat. 1998;5(5):333\u20139.","journal-title":"J Viral Hepat"},{"key":"135_CR14","first-page":"441","volume":"29","author":"P Colombutto","year":"1997","unstructured":"Colombutto P, Oliveri F, Leandro G, et al. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Ital J Gastoenterol Hepatol. 1997;29:441\u20137.","journal-title":"Ital J Gastoenterol Hepatol"},{"key":"135_CR15","first-page":"1748","volume":"45","author":"F Toccaceli","year":"1998","unstructured":"Toccaceli F, Roseti S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology. 1998;45:1748\u201352.","journal-title":"Hepatogastroenterology"},{"key":"135_CR16","first-page":"17","volume":"61","author":"D Dybowska","year":"2007","unstructured":"Dybowska D, Halota W. Zastosowanie interferonu naturalnego (Alfaferone) w praktyce klinicznej\u2013do\u015bwiadczenia w\u0142asne. Przegl Epidemiol. 2007;61:17\u201322.","journal-title":"Przegl Epidemiol"},{"key":"135_CR17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-1241.2003.tb11390.x","volume":"57","author":"A Benci","year":"2003","unstructured":"Benci A, Caremani M, Tacconi D, et al. Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leukocyte interferon alpha treatment. Int J Clin Pract. 2003;57:16\u20139.","journal-title":"Int J Clin Pract"},{"key":"135_CR18","doi-asserted-by":"crossref","unstructured":"Ferrara F, Baldo V, Rosa Rizzotto E, et al. Interferon alpha 2b plus ribavirin for na\u00efve patients with HCV-related cirrhosis. J Hepatol. 2007;46:223.","DOI":"10.1016\/S0168-8278(07)62186-2"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s15010-011-0135-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:18:16Z","timestamp":1686187096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-011-0135-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,8]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1007\/s15010-011-0135-3","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,8]]}}}